Use of sublingual tacrolimus in adults undergoing hematopoietic cell transplant: A pilot study.
Heather Personett MayGabriel T BartooRobert C WolfMithun V ShahMark R LitzowWilliam J HoganHassan AlkhateebPublished in: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners (2021)
Results demonstrate reliable absorption with sublingual tacrolimus use in patients undergoing hematopoietic cell transplant. Sublingual administration may allow for avoidance of the undesirable complications of IV tacrolimus, such as increased toxicities, required hospitalization for continuous infusion, risk of dose conversion and dilution errors and increased cost.Trial Registry name: Use of Sublingual Tacrolimus in Adult Blood and Marrow Transplant Patients, NCT04041219https://clinicaltrials.gov/ct2/show/NCT04041219?term=NCT04041219&draw=2&rank=1.
Keyphrases
- allergic rhinitis
- patients undergoing
- single cell
- end stage renal disease
- bone marrow
- cell therapy
- ejection fraction
- chronic kidney disease
- newly diagnosed
- computed tomography
- low dose
- preterm infants
- prognostic factors
- peritoneal dialysis
- risk factors
- magnetic resonance
- positron emission tomography
- mesenchymal stem cells
- contrast enhanced
- young adults
- mass spectrometry
- phase ii
- liquid chromatography
- adverse drug
- high resolution
- electronic health record
- drug induced
- simultaneous determination